Gilotrif Survival Data for Del19 and L858R Patients has Implications for Treatment, Research | GenomeWeb

NEW YORK (GenomeWeb) – Overall survival analysis of EGFR mutation subpopulations in two trials involving Boehringer Ingelheim's Gilotrif (afatinib) shows that non-Asian patients with Del19 mutated non-small cell lung cancer tumors live significantly longer – a median of an additional year – on Gilotrif compared to chemotherapy.

Meanwhile, researchers led by Massachusetts General Hospital's Lecia Sequist didn't observe similar survival advantages in non-Asian patients with L858R mutations when they received Gilotrif compared to chemotherapy.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.